October 29, 2015, the IND registration of GMA204 was accepted by CDE, and an on-site inspection is about to start.

GMA204 is the first molecule of Gmax to move to IND filing. As the second generation of EGFR TKI for non-small cell lung cancer (NSCLC), GMA204 works better in EGFR wild type and T790 mutation tumor models compared with the first generation EGFR TKI. Moreover, GMA204 could penetrate through blood brain barrier (BBB), which could target the brain metastasis of lung cancer.